The chemokine CCL2, known to be involved in tumor progression and metastasis, has been studied as well, demonstrating that BRAF-targeted therapy decreases CCL2 gene expression and secretion, correlated with reduction in tumor size in a specific murine model of BRAF-mutated melanoma [137]. This evidence concerns the gene BRAF and neoplasm.